TScan Therapeutics, Inc. TCRX
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 7.03% | -61.75% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.03% | -61.75% | |||
| Cost of Revenue | 6.84% | 18.79% | |||
| Gross Profit | -6.83% | -31.82% | |||
| SG&A Expenses | -0.91% | 37.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.72% | 23.32% | |||
| Operating Income | -4.65% | -33.31% | |||
| Income Before Tax | -5.91% | -24.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.91% | -24.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.91% | -24.76% | |||
| EBIT | -4.65% | -33.31% | |||
| EBITDA | -4.74% | -34.59% | |||
| EPS Basic | 6.10% | -18.13% | |||
| Normalized Basic EPS | 6.11% | -29.38% | |||
| EPS Diluted | 6.10% | -18.13% | |||
| Normalized Diluted EPS | 6.11% | -29.38% | |||
| Average Basic Shares Outstanding | 12.78% | 5.62% | |||
| Average Diluted Shares Outstanding | 12.78% | 5.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||